We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · August 05, 2020

Pioglitazone/Exenatide Improves Beta Cell Function and Glycemic Control Compared With Basal/Bolus Insulin in Poorly Controlled T2DM

Diabetes, Obesity & Metabolism


Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes, Obesity & Metabolism
Combination Therapy With Pioglitazone/Exenatide Improves Beta Cell Function and Produces Superior Glycemic Control Compared to Basal/Bolus Insulin in Poorly Controlled T2DM: 3-Year Follow-Up of the Qatar Study
Diabetes Obes Metab 2020 Jul 30;[EPub Ahead of Print], M Abdul-Ghani, O Migahid, A Megahed, RA DeFronzo, E Al-Ozairi, A Jayyousi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading